Drawing for ROSSOSEQ

USPTO serial 79115209

ROSSOSEQ

Reviewed by CopyMark Law Group

Reg. 4441775Status 404
Filing date
Status date
Registration date
Dec 3, 2013
Examiner
BUONGIORNO, CHRISTOPHER L
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ROSSOSEQ?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Roberta S. Bren

Roberta S. Bren MUNCY, GEISSLER, OLDS & LOWE, P.C.4000 Legato Road, Suite 310Fairfax, VA 22033UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations and substances for the treatment of inflammatory skin conditions; veterinary and sanitary preparations and substances for the treatment of inflammatory skin conditions; chemical preparations for pharmaceutical purposes, namely, for the treatment of inflammation of the skin, pain and psoriasis; topical preparations, namely, liquids, gels, creams, lotions and sprays for the treatment of inflammation and pain; pharmaceutical preparations in the form of vesicles for the treatment of pain and inflammatory skin conditions; parenteral preparations, namely, sterile preparations in the form of vesicles for injection, infusion or implantation into the human body for the treatment of inflammatory skin conditions; chemical preparations in the form of vesicles, namely, liquids, gels, creams, lotions and sprays for the treatment of pain and inflammatory skin conditions for medical and veterinary purposes; pharmaceutical preparations being chemical membranes and chemical aggregates for medical and veterinary purposes; pharmaceutical preparations of arachidonic acids for the treatment of pain and inflammatory skin conditions; dispersions and dry preparations of liposomal active substance carriers for use as a pharmaceutical, cosmetic substance carrier, in the nature of a liquid, gel, cream, lotion or lipid; pharmaceutical cosmetic and veterinary substances for the treatment of pain and inflammatory skin conditions; pharmaceuticals for medical use for the treatment of pain and inflammatory skin conditions; topical and parenteral pharmaceutical lipids for the treatment of pain and inflammatory skin conditions; cosmeceutical preparations in the nature of medicated cosmetics; local anesthetics; topical cream for treating inflammatory skin conditions; medicated topical dispersions, medicated topical lotions, medicated topical ointments, medicated topical gels, medicated topical sprays, medicated topical lacquers and pharmaceutical solutions which form a film on the skin for the treatment of pain and inflammatory skin conditions; surfactants for medical use in the treatment of diseases affecting the immune system, inflammatory diseases, diseases of the skin, hair and ear, treatment of inflammation, atopic eczema, dishydrotic hand eczema, plaque-type psoriasis, seborrhoeic eczema, acne vulgaris, pain or fungal infection, and disorders related to the skinSECTION 71 - CANCELLED—
010Medical devices in the nature of a carrier with nanostructures which cross through the skin for the treatment of dermal conditions associated with deep layers of the skin beneath the epidermis; molecular filtering devices for medical use, namely, a gel, liquid or cream preparation as a drug delivery device which filters through the skin and has a physical therapeutic effect at the point of complaint; medical, veterinary and surgical devices, namely, a medical device which acts as a drug delivery device in the nature of non-pharmaceutical nanostructures that migrate through the skin, which is used to reduce irritation, swelling or inflammation and target the symptoms of inflammatory skin conditions; inhalers for medical purposes sold empty; injection devices, namely, medical fluid injectors and medical syringes; medical instruments and devices for the administration of skin disease therapy and prophylaxis preparations and substancesSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 1, 2022DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Oct 1, 2022DETHDEATH OF INTERNATIONAL REGISTRATION—
Jan 22, 2022INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Dec 23, 2021INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Dec 22, 2021INPCINVALIDATION PROCESSED—
Oct 26, 2021INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Feb 26, 2021C71TCANCELLED SECTION 71—
Jan 3, 2020NREPNEW REPRESENTATIVE AT IB RECEIVED—
Dec 3, 2018REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Mar 14, 2016ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 14, 2016REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Mar 21, 2014FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Mar 4, 2014FICSFINAL DISPOSITION NOTICE SENT TO IB—
Mar 4, 2014FIMPFINAL DISPOSITION PROCESSED—
Mar 3, 2014FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Dec 3, 2013R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 17, 2013NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 17, 2013PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 15, 2013GPNXNOTIFICATION PROCESSED BY IB—
Aug 28, 2013OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Aug 28, 2013OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Aug 28, 2013NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 14, 2013PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Aug 7, 2013CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 23, 2013TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 23, 2013CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 22, 2013ALIEASSIGNED TO LIE—
Jul 15, 2013TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 6, 2013GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 6, 2013GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 6, 2013CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 12, 2013TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 12, 2013CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 12, 2013TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 11, 2013ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 11, 2013REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 1, 2012RFNTREFUSAL PROCESSED BY IB—
Aug 14, 2012RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Aug 14, 2012RFRRREFUSAL PROCESSED BY MPU—
Aug 14, 2012RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Aug 14, 2012MAFRAPPLICATION FILING RECEIPT MAILED—
Aug 13, 2012CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 8, 2012DOCKASSIGNED TO EXAMINER—
Aug 8, 2012NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 2, 2012REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance